INmune Bio, Inc.
INMB · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.03 | -0.00 | -0.92 | 0.09 |
| FCF Yield | -10.23% | -15.02% | -3.88% | -10.58% |
| EV / EBITDA | -4.40 | -2.59 | -15.82 | -9.06 |
| Quality | ||||
| ROIC | -28.09% | -83.81% | -32.99% | -29.15% |
| Gross Margin | 0.00% | 0.00% | 100.00% | 0.00% |
| Cash Conversion Ratio | 0.84 | 0.30 | 0.70 | 1.19 |
| Growth | ||||
| Revenue 3-Year CAGR | -39.34% | -43.62% | -41.44% | -66.55% |
| Free Cash Flow Growth | 30.31% | -18.42% | 38.04% | -57.64% |
| Safety | ||||
| Net Debt / EBITDA | 4.14 | 4.09 | 1.92 | 2.23 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 2,548.80 | 0.00 |